share_log

Panbela Therapeutics | 8-K: Current report

SEC announcement ·  Feb 13 17:35
Summary by Moomoo AI
On February 7, 2024, Panbela Therapeutics, Inc. reported to the SEC that its Compensation Committee approved retention bonuses for employees, including CEO Jennifer K. Simpson and CFO Susan Horvath. The bonuses are contingent on employment through August 15, 2024, or until a change in control of the company occurs. Simpson and Horvath are set to receive $54,281 and $34,299 respectively. Additionally, the Committee certified the cash incentive compensation for fiscal year 2023, with Horvath receiving $119,394. Despite being eligible for $227,084, Simpson waived her cash incentive for 2023. The retention agreement details were filed with the SEC and are incorporated into the report.
On February 7, 2024, Panbela Therapeutics, Inc. reported to the SEC that its Compensation Committee approved retention bonuses for employees, including CEO Jennifer K. Simpson and CFO Susan Horvath. The bonuses are contingent on employment through August 15, 2024, or until a change in control of the company occurs. Simpson and Horvath are set to receive $54,281 and $34,299 respectively. Additionally, the Committee certified the cash incentive compensation for fiscal year 2023, with Horvath receiving $119,394. Despite being eligible for $227,084, Simpson waived her cash incentive for 2023. The retention agreement details were filed with the SEC and are incorporated into the report.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more